Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CXCL6 Biologics Sequence Review Report 2026: C-X-C motif chemokine 6 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL6 Biologics Sequence Review Report 2026: C-X-C motif chemokine 6 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCL5 Biologics Sequence Review Report 2026: C-X-C motif chemokine 5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL5 Biologics Sequence Review Report 2026: C-X-C motif chemokine 5 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCL17 Biologics Sequence Review Report 2026: C-X-C motif chemokine 17 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL17 Biologics Sequence Review Report 2026: C-X-C motif chemokine 17 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCL16 Biologics Sequence Review Report 2026: C-X-C motif chemokine 16 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL16 Biologics Sequence Review Report 2026: C-X-C motif chemokine 16 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL16 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDR1 Biologics Sequence Review Report 2026: Cerebellar degeneration-related antigen 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDR1 Biologics Sequence Review Report 2026: Cerebellar degeneration-related antigen 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CDR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD99L2 Biologics Sequence Review Report 2026: CD99 antigen-like protein 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD99L2 Biologics Sequence Review Report 2026: CD99 antigen-like protein 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD99L2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD9 Biologics Sequence Review Report 2026: CD9 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD9 Biologics Sequence Review Report 2026: CD9 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD8B2 Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD8 beta-2 chain Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD8B2 Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD8 beta-2 chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD8B2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD83 Biologics Sequence Review Report 2026: CD83 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD83 Biologics Sequence Review Report 2026: CD83 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD83 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD82 Biologics Sequence Review Report 2026: CD82 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD82 Biologics Sequence Review Report 2026: CD82 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD82 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD81 Biologics Sequence Review Report 2026: CD81 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD81 Biologics Sequence Review Report 2026: CD81 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD81 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD74 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen gamma chain Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD74 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen gamma chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD74 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →